After nearly 15 years with one enzyme replacement therapy, two next-generation ERTs now compete to displace alglucosidase alfa across US late-onset Pompe disease.
Pompe disease is treated with enzyme replacement therapy (ERT) — recombinant acid alpha-glucosidase that clears the lysosomal glycogen driving progressive muscle and respiratory decline. For nearly 15 years the US late-onset (LOPD) market had a single ERT, alglucosidase alfa (Lumizyme/Myozyme, Sanofi), approved for infantile-onset in 2006 and late-onset in 2010. The commercial story since 2021 is a generational transition: two next-generation ERTs now compete to displace that incumbent. Avalglucosidase alfa (Nexviazyme, Sanofi), engineered for enhanced mannose-6-phosphate receptor targeting, was approved in August 2021; cipaglucosidase alfa co-administered with the oral chaperone miglustat (Pombiliti + Opfolda, Amicus) followed in September 2023.
In the head-to-head COMET trial, avalglucosidase alfa was non-inferior to alglucosidase alfa on forced vital capacity (+2.89% vs +0.46% predicted at week 49) and produced a numerically greater 6-minute-walk improvement (a +30.0 m between-group difference), though pre-specified statistical superiority was not reached. Cipaglucosidase alfa plus miglustat (PROPEL) improved the 6-minute walk by 20.8 m versus 7.2 m for alglucosidase alfa but likewise did not meet superiority on its primary endpoint. All three agents are intravenous infusions routed to the Medicare Part B medical benefit, and Pombiliti additionally requires the oral chaperone Opfolda — a two-product, split-benefit regimen. The contest is therefore fought less on trial superiority than on switching economics, infusion and monitoring burden, and payer step-edit policy.
FDA-approved enzyme replacement therapies for late-onset Pompe disease — United States, 2026
| Drug (Brand / INN) | Mechanism / Route | Company | US Approval | Key Trial Result (verified) |
|---|---|---|---|---|
| Nexviazyme (avalglucosidase alfa) | Next-gen recombinant GAA, high M6P · IV infusion | Sanofi | Aug 2021 (LOPD) | COMET: FVC +2.89% vs +0.46% predicted (non-inferior; superiority not reached); 6MWT +30.0 m vs alglucosidase at wk 49 |
| Pombiliti + Opfolda (cipaglucosidase alfa + miglustat) | Next-gen GAA + oral chaperone · IV + oral | Amicus Therapeutics | Sep 2023 (LOPD) | PROPEL: 6MWT +20.8 m vs +7.2 m for alglucosidase (primary-endpoint superiority not reached) |
| Lumizyme / Myozyme (alglucosidase alfa) | First-gen recombinant GAA · IV infusion | Sanofi | 2006 (IOPD) / 2010 (LOPD) | LOTS: 6MWT +28.1 m and FVC +3.4 pts vs placebo at 78 wks (treatment-naïve LOPD) |
Sources: FDA Drugs@FDA (approval status and dates); COMET, Lancet Neurol 2021 (PMID 34800399); PROPEL, Lancet Neurol 2021 (PMID 34800400); LOTS, NEJM 2010 (PMID 20393176). Annual WAC per manufacturer disclosures 2023.
What this brief answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- Mechanism and M6P-targeting differences across alglucosidase alfa, avalglucosidase alfa and cipaglucosidase alfa
- verified COMET, PROPEL and LOTS efficacy on FVC and 6-minute walk
- infusion, chaperone and monitoring burden by agent
Delivers
- Next-gen adoption dynamics among incident and switch patients
- the clinical-differentiation argument from COMET versus the reality that superiority was not formally reached
- prescriber switching considerations in a chronic infused market
Delivers
- Step-edit-from-Lumizyme requirements by plan
- the two-product Pombiliti + Opfolda split-benefit coordination barrier
- how access friction, not trial data, is arbitrating share
Custom brief delivered in 72 hours.
Commission This BriefWhat's inside
- Why alglucosidase alfa (Lumizyme) held the US LOPD market alone for nearly 15 years after 2006/2010 approval.
- How Nexviazyme's 2021 and Pombiliti+Opfolda's 2023 approvals opened a two-agent challenge to the incumbent ERT.
- How avalglucosidase alfa's enhanced mannose-6-phosphate receptor targeting differentiates it mechanistically from first-gen alglucosidase.
- Why Pombiliti's cipaglucosidase alfa requires co-administration with the oral chaperone Opfolda (miglustat), unlike the other two ERTs.
- Why COMET showed avalglucosidase's +30.0 m six-minute-walk edge yet fell short of pre-specified statistical superiority.
- How PROPEL's 20.8 m versus 7.2 m six-minute-walk gap for cipaglucosidase plus miglustat also missed its primary superiority endpoint.
- Why the fight to displace Lumizyme turns on switching economics rather than head-to-head trial superiority.
- How infusion and monitoring burden differences between the three ERTs factor into prescriber switching decisions.
- Why all three Pompe ERTs route through the Medicare Part B medical benefit as intravenous infusions.
- How Pombiliti's split-benefit design, pairing IV cipaglucosidase with oral Opfolda, creates a Part B/Part D coordination barrier.
- Why three FDA-approved enzyme replacement therapies now compete for the late-onset Pompe population, per Drugs@FDA records.
- How Pompe ERT's ~$400K+ annual per-patient WAC ranks among the highest-cost chronic infused therapy classes.
Included with every brief
How AXLRx builds this brief
Prepared by MoatRx analysts.
Every AXLRx brief is built from primary regulatory sources (FDA Drugs@FDA, ClinicalTrials.gov), peer-reviewed literature, and live payer and HTA documentation — not secondary summaries, market-research reports, or unverified estimates. Findings are independently verified before inclusion; if a figure cannot be sourced to a live record, it does not ship.
US Pompe Disease Competitive Intelligence sources: FDA Drugs@FDA (approval status and dates); primary trial publications in the Lancet Neurology and NEJM — COMET (PMID 34800399), PROPEL (PMID 34800400), and LOTS (PMID 20393176); ClinicalTrials.gov registrations; and manufacturer pricing disclosures.
- Avalglucosidase alfa versus alglucosidase alfa results verified against COMET, Lancet Neurol 2021 (PMID 34800399)
- Cipaglucosidase alfa plus miglustat results verified against PROPEL, Lancet Neurol 2021 (PMID 34800400)
- Alglucosidase alfa late-onset efficacy verified against LOTS, NEJM 2010 (PMID 20393176)
- Approval status, indications and dates verified against FDA Drugs@FDA
Frequently asked questions
Commission this brief
AXLRx delivers US late-onset Pompe disease competitive intelligence built for pharma and biotech commercial, access, and medical affairs teams. Custom brief in 72 hours.
Use the intake form to specify your indication, geography, and commercial question.
AXLRx analyst confirms scope, comparators, and delivery format.
Research-verified brief in 72 hours with optional analyst readout.